Oral Mucositis - Pipeline Insight, 2022

DelveInsight’s, “Oral Mucositis - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Oral Mucositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Oral Mucositis Understanding
Oral Mucositis: Overview
Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastro-intestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body passages that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus. The part of this lining that covers the mouth, called the oral mucosa, is one of the most sensitive parts of the body and is particularly vulnerable to chemotherapy and radiation. The oral cavity is the most common location for mucositis. Oral mucositis is probably the most common, debilitating complication of cancer treatments, particularly chemotherapy and radiation. It can lead to several problems, including pain, nutritional problems as a result of inability to eat, and increased risk of infection due to open sores in the mucosa. It has a significant effect on the patient’s quality of life and can be dose-limiting (i.e., requiring a reduction in subsequent chemotherapy doses).

""Oral Mucositis - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oral Mucositis pipeline landscape is provided which includes the disease overview and Oral Mucositis treatment guidelines. The assessment part of the report embraces, in depth Oral Mucositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oral Mucositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Oral Mucositis R&D. The therapies under development are focused on novel approaches to treat/improve Oral Mucositis.

Oral Mucositis Emerging Drugs Chapters
This segment of the Oral Mucositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Oral Mucositis Emerging Drugs
• GC4419: Galera Therapeutics
GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The drug is currently in phase III stage of clinical trial evaluation to treat Oral Mucositis.

• SGX942: Soligenix
SGX942 is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis. Administered twice weekly by a brief 4-minute IV infusion during chemoradiation treatment while patients are otherwise present at their clinician’s office or hospital, SGX942 may be a clinically convenient and safe approach to mitigating oral mucositis. Company’s pivotal Phase 3 clinical study (“DOM-INNATE”) for oral mucositis in head and neck cancer patients has completed enrollment.
Further product details are provided in the report……..

Oral Mucositis: Therapeutic Assessment
This segment of the report provides insights about the different Oral Mucositis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Oral Mucositis
There are approx. 10+ key companies which are developing the therapies for Oral Mucositis. The companies which have their Oral Mucositis drug candidates in the most advanced stage, i.e. phase III include, Soligenix.

• Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Oral Mucositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Oral Mucositis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Oral Mucositis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oral Mucositis drugs.

Oral Mucositis Report Insights
• Oral Mucositis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Oral Mucositis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Oral Mucositis drugs?
• How many Oral Mucositis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oral Mucositis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oral Mucositis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oral Mucositis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Galera Therapeutics
• Soligenix
• Izun Pharma
• MitoImmune Therapeutics
• Tosk
• Cellix Bio
• Enzychem Lifesciences
• Monopar Therapeutics

Key Products
• GC4419
• SGX942
• IZN-6N4
• MIT-001
• TK 112690
• Bupivacaine
• EC-18
• Clonidine HCl Mucoadhesive Buccal Tablet

Companies

• Galera Therapeutics
• Soligenix
• Izun Pharma
• MitoImmune Therapeutics
• Tosk
• Cellix Bio
• Enzychem Lifesciences
• Monopar Therapeutics